Abstract: Triple-negative breast cancer (TNBC) is an aggressive cancer subtype characterized by high rates of metastasis, poor prognosis, and drug resistance, largely driven by breast cancer stem cells (BCSCs). The Notch signaling pathway plays a fundamental role in the self-renewal of BCSCs and tumor angiogenesis. LY411575 is a gamma-secretase inhibitor (GSI) that targets this pathway by preventing the cleavage and activation of the Notch intracellular domain (NICD). While LY411575 and similar GSIs are not highly cytotoxic on their own, they are valuable in potentiating the effects of other chemotherapeutic agents and eliminating resistant BCSCs. However, the clinical application of LY411575 is currently hindered by poor bioavailability and severe off-target side effects, including gastrointestinal and cardiovascular toxicities. Future therapeutic strategies focus on encapsulating GSIs like LY411575 in targeted nanocarriers, such as solid lipid nanoparticles (SLNs) functionalized with DR-5 and DLL-4 monoclonal antibodies, to enhance site-specific delivery, improve bioavailability, and minimize systemic toxicity.
1. Introduction
Triple-negative breast cancer (TNBC) is a highly aggressive and heterogeneous cancer subtype defined by the lack of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptors (HER2) [1]. TNBC is associated with high rates of metastasis, poor prognosis, and significant drug resistance. Conventional chemotherapies primarily target rapidly dividing bulk tumor cells (non-BCSCs) but often fail to eradicate a small subpopulation of breast cancer stem cells (BCSCs) [1]. These surviving BCSCs are responsible for tumor recurrence and metastasis through the epithelial-to-mesenchymal transition (EMT) process [1].
The Notch signaling pathway has been identified as a fundamental regulator of angiogenesis in non-BCSCs and is crucial for the self-renewal and maintenance of BCSCs [1]. To combat this, researchers have evaluated gamma-secretase inhibitors (GSIs), including LY411575, as a targeted approach in TNBC to control tumor growth, prevent BCSC self-renewal, and suppress drug resistance [1].
2. Pharmacological Activity
LY411575 belongs to a class of drugs known as gamma-secretase inhibitors (GSIs), which also includes compounds like DAPT, RO4929097, and MK0752 [1]. Studies indicate that while LY411575 and other GSIs are not significantly cytotoxic as monotherapies, they possess potent pharmacological activity when used in combination treatments [1]. Specifically, LY411575 is useful in potentiating the cytotoxic effects of other anticancer agents [1]. By inhibiting the genes involved in chemoresistance (such as Hes and Hey), GSIs sensitize TNBC cells to conventional chemotherapy [1]. Furthermore, LY411575 plays a critical role in eliminating the BCSC population, inhibiting the EMT process, and reducing tumor angiogenesis and overall tumor growth [1].
3. Molecular Mechanism of Action
The primary molecular target of LY411575 is the gamma-secretase enzyme, which is highly expressed in TNBC cells and is integral to the Notch signaling pathway [1]. Under pathological conditions in TNBC, transmembrane ligands such as delta-like ligand 4 (DLL4) bind to Notch receptors (Notch1/Notch4) on the cell surface [1]. This binding triggers a proteolytic cleavage of the Notch receptor by the presenilin-dependent gamma-secretase complex [1].
This cleavage releases the Notch intracellular domain (NICD), which translocates to the nucleus, heterodimerizes with the transcription factor CSL, and activates target genes such as HES1, HEY2, MYC, CCND1, and others [1]. The activation of these genes promotes cell proliferation, angiogenesis, resistance to apoptosis, and the self-renewal of BCSCs [1]. LY411575 acts by inhibiting the gamma-secretase enzyme, thereby preventing the cleavage and release of NICD. By controlling NICD levels, LY411575 effectively silences tumor-promoting Notch signaling, leading to the inhibition of BCSC proliferation, differentiation, and metastasis [1].
4. Structure-Activity Relationship (SAR)
The provided literature does not contain specific information regarding the chemical structure or the Structure-Activity Relationship (SAR) of LY411575.
5. Current Limitations
Despite their therapeutic potential, the clinical application of GSIs like LY411575 is severely restricted by significant limitations. A major challenge is their poor bioavailability [1]. More critically, because gamma-secretase is involved in various normal physiological processes, systemic administration of GSIs is associated with severe off-target side effects [1]. These adverse effects include diarrhea, suppression of lymphopoiesis, headache, hypertension, fatigue, and ventricular dysfunctions [1]. These toxicities currently limit the widespread clinical use of LY411575 in oncology [1].
6. Future Perspectives
To overcome the clinical limitations of LY411575 and other GSIs, future research is heavily focused on targeted drug delivery systems. One promising approach is the encapsulation of GSIs in solid lipid nanoparticles (SLNs) [1]. SLNs offer advantages such as improved drug stability, higher entrapment efficacy, biocompatibility, and enhanced bioavailability [1].
To achieve site-specific delivery and minimize off-target side effects, researchers propose functionalizing these SLNs with monoclonal antibodies (mAbs) targeting unique TNBC surface proteins, specifically Death receptor-5 (DR-5) and DLL4 [1]. A dual-targeted delivery system would allow the LY411575 cargo to be delivered precisely to TNBC cells via receptor-mediated endocytosis [1]. Furthermore, combining a GSI like LY411575 with an anti-DLL4 mAb is expected to produce synergistic benefits, simultaneously blocking Notch-mediated BCSC proliferation and inducing proapoptotic effects, ultimately leading to more effective eradication of TNBC when combined with conventional chemotherapy [1].
7. References
